Skip to main content

Hereditary Hemochromatosis

3
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
Deferasirox FCTPhase 21 trial
Active Trials
NCT03203850Terminated45Est. Apr 2023
Bond Biosciences
Bond BiosciencesMO - Parkville
2 programs
1
1
BBI-001Phase 1/21 trial
BBI-001Phase 11 trial
Active Trials
NCT05238207Terminated24Est. May 2023
NCT07371793Not Yet Recruiting34Est. Feb 2027
Protagonist Therapeutics
Protagonist TherapeuticsAustralia - Brisbane
1 program
PTG-300PHASE_21 trial
Active Trials
NCT04202965Completed16Est. Feb 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Protagonist TherapeuticsPTG-300
SandozDeferasirox FCT
Bond BiosciencesBBI-001
Bond BiosciencesBBI-001

Clinical Trials (4)

Total enrollment: 119 patients across 4 trials

NCT04202965Protagonist TherapeuticsPTG-300

PTG-300 in Subjects With Hereditary Hemochromatosis

Start: Mar 2020Est. completion: Feb 202216 patients
Phase 2Completed
NCT03203850SandozDeferasirox FCT

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

Start: Jan 2018Est. completion: Apr 202345 patients
Phase 2Terminated
NCT07371793Bond BiosciencesBBI-001

A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis

Start: Mar 2026Est. completion: Feb 202734 patients
Phase 1/2Not Yet Recruiting
NCT05238207Bond BiosciencesBBI-001

A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers

Start: Mar 2022Est. completion: May 202324 patients
Phase 1Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.